Published 5 May 2009, doi:10.1136/bmj.b1852
Cite this as: BMJ 2009;338:b1852

News

Report calls for end of drug promotion to doctors

Bob Roehr

1 Washington, DC

The first 150 words of the full text of this article appear below.

Product promotion among doctors by drug companies and medical device manufacturers should be virtually eliminated, and remaining research and educational ties should become completely transparent, a new report from the US Institute of Medicine recommends.

The institute’s president, Harvey Fineberg, said that the report "sets a new standard for comprehensiveness" across the spectrum of activity—from research and treatment guidelines to education and training of healthcare professionals and regular clinical practice.

He said he was particularly pleased that the report focuses on "prevention and anticipation, as opposed simply to responding after the fact to these problems."

Bernard Lo, a medical ethicist at the University of California, San Francisco, chaired the committee that wrote the report. He said that conflicts of interest are "a vital issue that goes to the heart of patient trust." The recommendations "reinforce and advance" those made by more than a dozen other groups over the past few . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Access jobs at BMJ Careers
Whats new online at Student BMJ